Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Albuterol HFA-BOI · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Albuterol HFA-BOI | EXPERIMENTAL | - |
| Albuterol HFA-MDI | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Albuterol HFA-BOI | DRUG | Albuterol HFA breath operated inhaler, 90 mcg/sprau |
| Albuterol HFA-MDI | DRUG | Albuterol HFA multi-dose inhaler |
Inclusion Criteria: * Asthma diagnosed ≥6 months prior and stable for 4 weeks prior to screening * Poor inhaler coordination as assessed at screening * Reversible bronchoconstriction (≥ 12% increase in FEV1) Exclusion Criteria: * Albuterol allergy * Investigational drug within 30 days * Injected ...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 27 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | tilrekimig and rHuPH20, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
Albuterol HFA-BOI is an investigational breath-operated albuterol inhaler being developed by Teva Pharmaceutical Industries Limited for asthma. It is a small molecule formulation designed to deliver albuterol, a short-acting beta-agonist, through a breath-actuated device. It is in Phase 2 clinical development and has not been approved by the FDA.
Albuterol HFA-BOI is being studied for use in asthma patients, specifically those with poor inhaler technique. The breath-operated design aims to deliver albuterol reliably when the patient inhales. It is an investigational product and is not yet approved for any indication.
Albuterol HFA-BOI targets the beta-2 adrenergic receptor, also known as ADRB2. It acts as an agonist at this receptor, which is the same mechanism as standard albuterol. This receptor activation leads to bronchodilation in the airways.
Albuterol HFA-BOI is being developed by Teva Pharmaceutical Industries Limited, which trades under the ticker TEVA. Teva is the sponsor of the clinical program for this breath-operated albuterol inhaler.
Albuterol HFA-BOI is in Phase 2 clinical development. It is an investigational product and has not been approved by the FDA. The Phase 2 trial has been completed, and no active trials are currently listed.
Albuterol HFA-BOI has been studied in one completed Phase 2 trial, NCT00054964, titled Comparative Effectiveness of a Breath-operated Albuterol Inhaler in Asthma Patients With Poor Inhaler Technique. The trial enrolled 14 adults in the United States and used an active-controlled, randomized design.